Epix Will Resubmit Vasovist NDA By Mid-Year
This article was originally published in The Pink Sheet Daily
Executive Summary
End appears near in long road to approval for vascular imaging agent after FDA and Epix agree on plan for Phase III study image re-reads.
You may also be interested in...
Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million
Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.
Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million
Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.
Epix Drops Depression Candidate After Second Study Failure
Alzheimer’s candidate in development with GlaxoSmithKline advances.